Affordable Access

deepdyve-link
Publisher Website

Sirolimus in a Renal Transplant Recipient Infected With COVID-19: A Blessing in Disguise?

Authors
  • Talwar, Dhruv1
  • Kumar, Sunil1
  • Acharya, Sourya1
  • Hulkoti, Vidyashree1
  • Annadatha, Akhilesh1
  • 1 Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, IND
Type
Published Article
Journal
Cureus
Publisher
Cureus, Inc.
Publication Date
Aug 11, 2021
Volume
13
Issue
8
Identifiers
DOI: 10.7759/cureus.17102
PMID: 34527488
PMCID: PMC8432414
Source
PubMed Central
Keywords
Disciplines
  • Pulmonology
License
Unknown
External links

Abstract

Immunocompromised status Is often associated with severe coronavirus infection given the inability of the immune system to combat the deadly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with multiple comorbidities such as diabetes mellitus, hypertension, and chronic kidney disease along with patients on immunosuppressants or chemotherapy are at higher risk of getting infected during the ongoing pandemic with more probability of adverse outcomes. However, we report a rare case of a renal transplant recipient who was on sirolimus and contracted coronavirus disease (COVID-19). His immunosuppressants were continued and he was managed with antiviral, steroids and low molecular weight heparin and the patient responded well to the treatment and recovered completely after a span of one week. Use of sirolimus in a patient with renal transplant recipient helped in preventing intensification of the severity in COVID-19 attributing to its inhibiting effect on mammalian target of rapamycin (mTOR) which he was using post his renal transplant, therefore, proving to be a blessing in disguise.

Report this publication

Statistics

Seen <100 times